Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Deucravacitinib helped a man regrow hair and improve psoriasis.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Systemic lupus erythematosus treatment can restore vision in patients with retinal artery occlusion.

BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Canakinumab's effect on COVID-19 outcomes is unclear.

All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.

Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Oral bicalutamide is safe and effective for female hair loss.

Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.

Apremilast improved symptoms in patients with severe skin conditions.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.

Deucravacitinib helped a man regrow hair significantly.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.